Research has suggested that Victoza and other Type 2 diabetes medications called incretin mimetics may harm the pancreas, leading to pancreatic cancer or pancreatitis. Hundreds of product liability claims have been filed in U.S. courts on behalf of patients who were allegedly harmed by these drugs.
Bernstein Liebhard LLP is evaluating legal claims on behalf of Victoza patients who were diagnosed with pancreatitis or pancreatic cancer. To learn more about filing a Victoza lawsuit, please contact our office at (888) 994-5118.
Victoza (liraglutide) is a once-daily, injectable diabetes medication used to help control blood sugar in adults with Type 2 diabetes. When the U.S. Food & Drug Administration (FDA) approved Victoza in 2010, it did so against the advice of two of its own expert committees. Among other things, the FDA’s advisors were concerned about Victoza’s association with pancreatitis and thyroid tumors.
In June 2011, the FDA updated the Victoza label to warn patients about the increased risk of pancreatitis, thyroid cancer, and kidney failure. In 2013, the agency announced it was investigating a possible link between incretin mimetics and an increased risk of pancreatic cancer. Read More
Public Citizen, a consumer advocacy group dedicated to patient safety, has repeatedly petitioned the FDA to ban Victoza:
As of January 2016, more than 750 legal claims had been filed on behalf of patients who were diagnosed with pancreatitis or pancreatic cancer while taking an incretin mimetic to treat Type 2 diabetes. The majority of these cases have been centralized in a multidistrict litigation that is currently underway in the U.S. District Court, Southern District of California (MDL No. 2452). Read More
Bernstein Liebhard LLP is offering free legal reviews to individuals interested in filing a Victoza lawsuit. If you or a loved one were diagnosed with pancreatic cancer or pancreatitis while using this medication, please contact our legal staff today by calling (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.